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Ties Hoomans1,2* and Johan L Severens1,3Abstract
Economic evaluations can inform decisions about the efficiency and allocation of resources to implementation
strategies—strategies explicitly designed to inform care providers and patients about the best available research
evidence and to enhance its use in their practices. These strategies are increasingly popular in health care,
especially in light of growing concerns about quality of care and limits on resources. But such concerns have hardly
motivated health authorities and other decision-makers to spend on some form of economic evaluation in their
assessments of implementation strategies. This editorial addresses the importance of economic evaluation in the
context of implementation science—particularly, how these analyses can be most efficiently incorporated into
decision-making processes about implementation strategies.
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Introduction
Economic evaluation assesses the efficiency and allocation
of resources to interventions that may improve health care
and health outcomes. Economic evaluation applies not
only to decisions about interventions or services that
directly target patients, like pharmacological treatments
and medical devices, but also to decisions about imple-
mentation strategies, which are explicitly designed to
inform care providers and patients about the best avail-
able research evidence and to enhance its use in their
practices.
Many inefficiencies in health-care delivery result from
overuse of unnecessary services, underuse of beneficial
interventions, or medical errors [1]. In light of the growing
concerns about the quality of care and budgetary pres-
sures, implementation strategies are used to improve ser-
vice delivery and outcomes. Potentially effective strategies
that can promote an uptake of services can be as straight-
forward as clinical decision support, education and financial
incentives—or can be as complex as total quality manage-
ment and reforms of health-care systems.* Correspondence: thoomans@medicine.bsd.uchicago.edu
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article, unless otherwise stated.Empirical studies of the effects of implementation strat-
egies related to behavior change and health outcomes have
become more numerous [2,3]. Many explore how to most
effectively address particular problems of implementation,
a question that may be answered with insights into the
mechanisms by which implementation works and the use
of behavior change theory, from disciplines such as
psychology and sociology [4,5].
But although the prominence of implementation science
in health services is increasing, relatively little attention
has been paid to another important aspect of implementa-
tion strategies: these efforts demand resources, and thus,
have costs. Depending on the perspective of the decision-
maker and their objective(s), the cost of implementation
may include the following: 1) costs associated with execut-
ing implementation strategies; 2) the excess cost of ser-
vice delivery as uptake or implementation changes; 3)
the opportunity cost to providers and patients partaking
in the implementation activities; and 4) research and
development-related expenses resulting from the process
of implementing change in health care. Unless the budget
for implementation is sufficient, not all possible imple-
mentation projects can be supported. Trade-offs must be
made, and these trade-offs merit an analysis that can
compare costs to their benefits and that can identify
the opportunity cost of choices—in other words, an
economic evaluation.ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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evaluation in the context of implementation science—in
particular, how these analyses can be most efficiently
incorporated into decision-making processes about imple-
mentation strategies (Figure 1).Use of economic evaluation
Despite the prevalence of economic evaluation in health
services research, its use is not standard practice in
assessing implementation strategies. Recent reviews re-
vealed fewer than 60 studies of the efficiency of strat-
egies for implementing clinical practice guidance before
2008 [2,6,7], with no substantial progress since then.a
The number of economic evaluations contrasts sharply
with the number of studies on implementation strategies
assessing only their effect on behavior change and health
outcomes.
Why are implementation decisions so seldom guided by
economic evaluation? Some of the more plausible reasons
include divergent views on cost and cost-effectiveness,
limited resources for evaluative research, and the paucity
of data for decision-making.
Views on the appropriate role of economics in evaluat-
ing implementation strategies may differ importantly be-
tween people and over time. Some revert to basic ethical
tenets and moral obligations to discard information on
cost completely; others view, more realistically, consider-
ations of cost as secondary or complementary to other cri-
teria, such as clinical effectiveness. But regardless of the
differences of opinion and how they impact evaluation
and decision-making, particular implementation strategies
do have costs. Simply ignoring these implications can have
undesirable consequences, such as inefficiencies and in-
equities that compromise the accessibility and delivery of
health services—the very reason why spending on imple-
mentation of research evidence is considered initially.
Limits on research capacity and appropriate data seem
plausible reasons for decision-makers not to base imple-
mentation decisions on some form of economic evaluation,
but in fact conceal a paradox: implementation decisions
need economic evaluations that produce good-quality data
for these decisions to be well-informed; economic evalua-
tions need decisions that utilize their results for these eval-
uations to be supported.This is an invited editorial on a topic, which was p
Implementation Science. We encourage submissio
strategies or current practices, which include an ec
pertinent conceptual and methodological papers co
implementation science. 
Michel Wensing, Robbie Foy and Anne Sales 
Figure 1 Editors’ note.Methods of economic evaluation
Methods—cost/cost-consequences analysis, cost-effective-
ness/utility analysis, or cost-benefit analysis—do not need
to pose a burden to performing economic evaluation of
implementation strategies. The approach is similar to the
economic evaluation of the services being implemented,
while explicitly accounting for the resources used in devel-
oping and executing implementation strategies as a cost
of ensuring appropriate service delivery [8,9]. Determining
which method to use requires weighing potential uses in
resource-allocation decision-making versus its demand of
information and computational complexity (Table 1).
Cost and cost-consequences analysis
Common to all forms of economic evaluation is the ana-
lysis of cost. Properly conducted—collecting adequate data
on the use of all relevant resources on implementation
and assigning appropriate tariffs or prices to those re-
sources—cost analysis can help decision-makers address a
not unimportant question: How much more will it cost to
pursue implementation efforts? (Depending on the ques-
tion and the purpose of the cost information, costing may
require detailed analysis and such accuracy-focused meth-
odology as micro or activity-based costing.) But informa-
tion from cost analysis, such as budget impact analyses or
patient level cost-minimization studies, generally is insuffi-
cient to determine whether intervening in implementation
problem(s) makes economic sense. Unless the potential
alternative strategies are certain to have the same
health outcomes across provider and patient practices
over time—which is unlikely—implementation decisions
will require a joint comparison of costs and outcomes by
full economic evaluation.
At the simplest level, economic evaluation entails the
mere listing of all cost/benefit implications of each po-
tential choice, as in cost-consequences analyses [10].
This form of economic evaluation was applied in a trial-
based study of task substitution for diagnosing fibro-
myalgia in inpatients [11]. Compared to a specialist-led
process, a nurse-led process was reported to have higher
patient satisfaction scores, equivalent health outcomes,
and lower consumption of care and other resources.
Analyses like these have distinct uses. They provide
information for spending decisions to address problems
in health care, when possible implementation strategiesrioritized by the editorial board of 
ns of empirical studies of implementation 
onomic evaluation. We are also interested in 
ncerning economic evaluation as applied to 
Table 1 Overview of forms of economic evaluation
Form of evaluation Use for decision making Measurement of health effects Economic summary measure
Cost-consequences
analysis
Comparison of implementation
strategies that have disparate
outcomes
Any measure Not applicable
Cost-effectiveness
analysis
Comparison of implementation
strategies that produce a common
outcome
Process measures (e.g., professional guidance
adherence, patient compliance to medication)
or health effects (intermediate or final), measured
in natural units
Cost-effectiveness ratio (e.g., cost per
case averted, cost per life-year saved),
at patient or population level
Cost-utility analysis Comparison of implementation
strategies that have morbidity and
mortality outcomes
Final health outcomes, including health status,
patient preferences, utilities
Cost per quality-adjusted life-year, at
patient or population level
Cost-benefit analysis Comparison of implementation
strategies with different units of
outcome (health and nonhealth)
Monetary units Net health benefit or net monetary
benefit, at patient or population level
Cost analysis Comparison of net cost of
implementation strategies with
equivalent outcomes
Not applicable Net cost or cost of illness, at patient
or population level
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be combined meaningfully. Cost-consequences analyses
permit value judgments without having to fully specify a
relation between all the different measures of outcomes.
And yet listing the cost/benefit implications of imple-
mentation strategies alone fails an important objective of
economic evaluation—to make explicit the opportunity
costs of alternative resource uses.
Cost-effectiveness and cost-utility analyses
These opportunity costs can be assessed directly using
other forms of economic evaluation: cost-effectiveness or
cost-utility analyses. Incremental cost-effectiveness ratios
are established by dividing the difference in costs of various
implementation strategies by the corresponding difference
in health outcomes. Again, the measure(s) of outcomes
most appropriate for ratio calculations depends, to an im-
portant extent, on the objective of decision-making and
the perspective of analysis. Common metrics typically used
include incremental cost per life-year gain or per quality-
adjusted life-year (QALY).
Ratios of cost-effectiveness—absolute and relative—can
vary considerably across targeted providers, patients,
behaviors, practices, and services. A sample of cost-
effectiveness studies and calculated incremental cost-
effectiveness ratios are found in Table 2. These results
indicate that actively promoting and implementing
clinical guidance may provide an inefficient use of re-
sources, yield life-years or QALYs at additional cost,
or may even be cost-saving.
Wide variation in outcomes is not uncommon given the
many types of information inputs used in cost-effectiveness
studies. One obvious and important determinant is the
cost of implementation; economies of scale and scope may
apply as implementation strategies target larger groups
of providers and patients, and multiple behaviors andpractices. But the cost-effectiveness of such strategies also
depends critically on the effect they have on provider and
patient behaviors—as measured by guideline adherence
and patient compliance—and on the differential outcomes
of care between services being implemented. The greater
the difference in expected outcomes between usual care
and the change being implemented, and the more wide-
spread the implementation, the more likely a strategy is to
be cost-effective.
Translating cost-effectiveness ratios into resource allo-
cation decisions can be difficult—even when potential im-
plementation projects are comparable in scale and scope,
and information about all the analysis inputs is so precise
that the outcomes can be regarded as certain. Strategies
that improve health and lower costs should be accepted;
rejected should be those that worsen outcomes at higher
costs. But what if a strategy is expected to improve
(worsen) health outcomes but also cost more (less)?
In such cases, health or safety gains from implementa-
tion strategies need to be valued in monetary units,
reflecting the budget constraints and opportunity cost
of alternative resource uses. Common thresholds for
choices of pharmacological treatments and other health
services range from €20,000 to €80,000 per life-year or
QALY—and similar threshold values may well apply to
accept-reject decisions in an implementation context. Yet
the critical question is: Do current thresholds fully incorp-
orate the cost of implementation of ‘cost-effective’ health
services?
Cost-benefit analysis
When assigned appropriate thresholds, cost-effectiveness
data can be transformed to a more comprehensive meas-
ure of implementation strategy efficiency—the net bene-
fit. As earlier applications of this concept suggested
[14,15], the barriers to using so-called cost-benefit analysis
Table 2 Examples of incremental cost-effectiveness ratios and suggested decisions about implementation strategies
Study Comparison of
implementation
strategies
Intervention
considered for
implementation
Incremental
cost-effectiveness
ratio
Suggestions for
implementation
decision
Mason et al. 2005 [12] Specialist-nurse led
clinics versus usual care
Lipid control in patients
with diabetes versus no
lipid control
$19,950 per
quality-adjusted
life-year
Use of specialist-nurse led clinics
for implementing lipid control is
cost-effective
Scheeres et al. 2008 [13] Multifaceted strategy, including
health professional and patient
education and instruction, versus
usual care
Cognitive behavior therapy
of chronic fatigue syndrome
versus regular counseling
€5,320 per recovered
patient
Use of multifaceted strategy
for implementing cognitive
behavior therapy is cost-effective
Walker et al. 2009 [14] Financial incentives to primary
care practices versus usual care
Use of ACE inhibitor and
other quality indicators
versus conventional care
£5,623 per
quality-adjusted
life-year
Use of financial incentives for
implementing ACE inhibitor
and other quality indicators
is cost-effective
Hoomans et al. 2009 [15] Audit and feedback to primary
care physicians versus usual care
Intensive control of blood
glucose in patients with type
2 diabetes versus
conventional control
€25,640 per
quality-adjusted
life-year
Use of audit and feedback for
implementing intensified control
of blood glucose is cost-effective
Choudhry et al. 2011 [16] No co-payments for patients
versus co-payments
Preventive medication after
myocardial infarction versus
no preventive medication
$54 per nonfatal
vascular event or
vascularization
averted (cost-saving)
Use of no co-payments for
implementing preventive
medication is cost-effective
Mortimer et al. 2013 [17] Multifaceted strategy targeting
primary care physicians, including
interactive workshops, versus
guideline dissemination alone
Evidence-based care for
acute low back pain versus
convention
−AU$108 per x-ray
referral avoided
(cost-saving)
Use of multifaceted strategy for
implementing evidence-based
care is cost-effective
Gillespie et al. 2014 [18] Structured patient education
with group follow-up versus
individual follow-up
Self-management in type 1
diabetes versus conventional
care
€19,300 per
quality-adjusted life
year (cost-saving)
Use of structured patient
education with group for
implementing self-management
is not cost-effective
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be overcome by the analytic benefits it has to offer: i) direct
comparison of implementation projects of varying scale and
scope, and ii) detailed assessment of uncertainty in
implementation decision outcomes.
Toward efficient use of economic evaluation
Once the methods for evaluation (including cost-effective-
ness thresholds) are agreed upon, economic evaluation
becomes a useful tool in the studying and planning of
strategies for implementing change in health care. The
question then becomes as follows: How can economic
evaluation be performed most efficiently?
Limited collection of economic data
Economic evaluations are more efficient if data collection
on outcomes is limited. One approach is to confine the
study to the measures of the care process, say cost per
change in professional guidance adherence or patient com-
pliance to medication, instead of measuring actual health
outcomes. For example, in a Dutch quasi-experiment
on the use of financial incentives as an implementation
strategy [19], incentivizing primary care providers was
found to reduce prescriptions of targeted drugs, saving
costs in comparison to usual care. Because there was
also good evidence that denying patient medication didnot have (long-term) effects on health outcomes, the
incentive plan was likely to be a cost-effective strategy
to implement more conservative prescribing practices
in primary care.
Other ways to improve efficiency by limiting data collec-
tion include shortening the length of patient or provider
follow-up or by relying on studies of less rigorous design
for data collection.
However, limiting data collection can have undesirable
consequences, such as reducing confidence in the accur-
acy of the conclusions drawn from the analysis. Consider
the Dutch study of financial incentives [19]: can the estab-
lished cost-effectiveness ratios be considered the same
across all targeted care providers and prescription drugs?
Or do these ratios actually vary by provider, drug, baseline
prescriptions rate, or by some other source of heterogen-
eity? Has enough information been collected to ascertain
whether incentivizing providers’ prescribing practices will
have spillover effects to non-targeted behaviors and prac-
tices? Limiting the collection of economic data can in-
crease evaluative efficiency, but the potential biases in the
assessment of strategies need be carefully considered.
Use of decision analytic models
Practical considerations suggest yet another approach to
economic evaluation and efficiency improvement: the use
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nomic data on implementation strategies may be synthe-
sized from a range of sources, including theory on
behavioral change, rather than from a single trial or obser-
vational study. For example, in a Dutch study of the im-
plementation of intensified glycemic control in type 2
diabetes, the comparison of audit and feedback to primary
care providers versus usual care was based on an eco-
nomic model [15]. The model permitted establishing esti-
mates of incremental cost per QALY ratios by linking
behavior change to health-related outcomes using a simu-
lation of experiments.
Decision analytic models have many more uses along
these lines—for example, they can provide estimates of
the expected value of information to form a basis for de-
ciding whether additional data collection is necessary
[20,21]. Despite apparent benefits, the use of models in
economic evaluation and implementation choices re-
mains uncommon.Early assessment of implementation decisions
The greatest gain in efficiency for implementation deci-
sions may not be the method of economic evaluation
but rather the timing. Economic evaluations are typically
being performed ex-post—after some inefficiency has
been identified as a problem of implementation and after
designing and testing a set of strategies.
Instead of carrying out economic evaluations after the
fact, a 3-step ex-ante process of evaluation and decision-
making is potentially much more efficient:
Step 1: Assess the expected returns (as measured by
net benefit on a monetary or health scale) from
promoting the implementation of research evidence or
any further change in clinical management or health
policy through the use of value of implementation
analysis [15,20,21].
Step 2: Make predictions of the implementation cost,
which may include research and development-related
expenses and the opportunity cost of care providers
and patients partaking in the implementation activities.
Step 3: Set [1] against [2] before pursuing a more
elaborate process of evaluation and decision-making
regarding implementation strategies.
Early economic assessment can help eliminate cost-
ineffective implementation studies early on, allowing re-
sources to be directed toward problems in care where
intervening is likely to be more beneficial. Knowledge of
the practicality of health service implementation is es-
sential. If valid and meaningful estimates of resource allo-
cation requirements for implementation can be made, the
cost of implementation could be considered much soonerin the health-care decision-making process—namely, when
the decisions about care components are being made [22].
Conclusions
Performing economic evaluations is not rocket science.
Already commonly used in the assessment of health ser-
vices, economic evaluation is a potentially useful tool for
making decisions on strategies for implementing re-
search knowledge into clinical practice, management, or
health policy. Confronted with a problem of implemen-
tation, decision-makers who wish to derive the greatest
benefits from available resources must spend on some
form of economic evaluation. Only by comparing each
potential choice across both costs and benefits can the
opportunity cost of implementation strategies be
assessed. As more economic evaluations are performed
and decision-makers leverage analytic techniques such
as modeling and value of implementation analysis, the
contribution of economic evaluation to decision-making
processes will increase. The question is how economic
evaluation can most efficiently be incorporated into im-
plementation decisions, not whether it should.
Endnote
aA comprehensive search in PubMed for English lan-
guage publications from 1 January 2008 to 1 July 2014,
using the terms (in all fields): ‘economic eval* OR cost-
effect*’, ‘implementation strateg* OR quality improv*’, re-
vealed 284 records, most of which recorded publications
of studies that did not report any cost of implementation
or that refrained to perform an economic evaluation of
the reported implementation or quality improvement
strategy in terms of cost of implementation.
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